Benzinga | Mar 16, 2021 07:10AM EDT

AzurRx BioPharma Announces Completion Of Enrollment In Phase 2b OPTION 2 Clinical Trial Of MS1819 In Cystic Fibrosis; Top-line Data Expected By End Of Q1

DELRAY BEACH, Fla., March 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has completed enrollment for its Phase 2b OPTION 2 clinical trial to investigate MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI). The trial enrolled 30 CF patients and top line data from the study is anticipated by the end of Q1 2021.